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Abstract
Triple‐negative breast cancer (TNBC) has a relatively poor outcome. Acquired 
chemoresistance is a major clinical challenge for TNBC patients. Previously, we 
reported that kinase‐dead Aurora kinase A (Aurora‐A) could effectively transacti‐
vate the FOXM1 promoter. Here, we demonstrate an additional pathway through 
which Aurora‐A stabilizes FOXM1 by attenuating its ubiquitin in TNBC. Specifically, 
Aurora‐A stabilizes FOXM1 in late M phase and early G1 phase of the cell cycle, 
which promotes proliferation of TNBC cells. Knock‐down of Aurora‐A significantly 
suppresses cell proliferation in TNBC cell lines and can be rescued by FOXM1 over‐
expression. We observe that paclitaxel‐resistant TNBC cells exhibit high expression 
of Aurora‐A and FOXM1. Overexpression of Aurora‐A offers TNBC cells an addi‐
tional growth advantage and protection against paclitaxel. Moreover, Aurora‐A and 
FOXM1 could be simultaneously targeted by thiostrepton. Combination of thiostrep‐
ton and paclitaxel treatment reverses paclitaxel resistance and significantly inhib‐
its cell proliferation. In conclusion, our study reveals additional mechanism through 
which Aurora‐A regulates FOXM1 and provides a new therapeutic strategy to treat 
paclitaxel‐resistant triple‐negative breast cancer.
K E Y W O R D S
Aurora kinase A, cell cycle, chemotherapy, FOXM1, paclitaxel resistance, triple‐negative 
breast cancer
1  | INTRODUC TION
Triple‐negative breast cancer (TNBC) represents 15%–20% of newly 
diagnosed breast carcinoma and is characterized by low expression 
of progesterone receptor (PR), oestrogen receptor (ER) and human 
epidermal growth factor receptor 2 (HER2).1‐3 Patients with TNBC 
have a relatively poor outcome and cannot be treated with endocrine 
therapy or therapies targeted to HER2. Thus, to date, chemotherapy 
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remains the only possible therapeutic option in the treatment of 
TNBC.4,5 Paclitaxel is one of the most frequently used chemothera‐
peutic drug for TNBC.6 It disrupts normal microtubule dynamics and 
arrests cancer cells in mitosis. Although TNBC patients are initially 
responsive to paclitaxel, acquired chemoresistance is inevitable and 
put forward a major clinical challenge for patients that relapsed.7,8 
Thus, to elucidate the molecular mechanism of paclitaxel resistance 
and develop new combination drug therapy for TNBC are urgently 
needed to decrease TNBC‐related mortality.
Aurora kinase A (Aurora‐A) is a member of a serine/threonine 
kinase family involved in mitotic cell division and genetic insta‐
bility.9 Overexpression of Aurora‐A has been reported to partic‐
ipate in multi‐drug resistance.10‐12 Several studies have shown 
that aberrant expression of Aurora‐A is highly correlated with 
triple‐negative breast cancer (TNBC) and was a potential thera‐
peutic target for TNBC.3,13‐15 Aurora‐A exerts its function in can‐
cer through kinase‐dependent and kinase‐independent manner. In 
human neuroblastoma, Aurora‐A stabilizes N‐Myc and contributes 
to the development of neuroblastoma independently of its kinase 
activity.16 Aurora‐A was also reported to phosphorylate YAP and 
promotes YAP‐mediated transcription in TNBC.15 We reported 
previously that kinase‐dead Aurora‐A can play as a transcriptional 
co‐factor in nucleus to transactivate the FOXM1 promoter in breast 
cancer stem cell.17 FOXM1 was reported to mediate drug resistance 
and was highly up‐regulated in TNBC.18,19 To elucidate the underly‐
ing mechanism for Aurora‐A regulating FOXM1 in TNBC is important 
for the targeted therapy that aiming to block the critical oncogenic 
function of Aurora‐A.
In the present study, we demonstrate that Aurora‐A binds and 
stabilizes FOXM1 protein independently of its kinase activity. This 
function is critical for the growth of TNBC cells. We observed that 
overexpression of Aurora‐A mediated paclitaxel resistance in TNBC 
cells. Moreover, Aurora‐A and FOXM1 could be simultaneously tar‐
geted by thiostrepton which could overcome paclitaxel resistance 
in TNBC cells. Finally, aberrant expression of FOXM1 and Aurora‐A 
was found highly correlated in human triple‐negative breast cancer 
sample. Overall, our studies revealed additional mechanism through 
which Aurora‐A regulates FOXM1 and provided a new combination 
drug therapeutic strategy to treat paclitaxel‐resistant triple‐nega‐
tive breast cancer.
2  | MATERIAL S AND METHODS
2.1 | Cell culture and cell cycle arrest
Human breast cancer cell lines MDA‐MB‐231 and MCF‐7 were 
acquired from the American Type Culture Collection (Beijing 
Zhongyuan Ltd) and cultured in media as recommended by the 
provider. Paclitaxel‐resistant MDA‐MB‐231 cells were cultured 
in Dulbecco's modified Eagle's medium (Gibco, ThermoFisher 
Scientific) supplemented with 10% foetal bovine serum (Hyclone, 
ThermoFisher Scientific). The paclitaxel‐resistant cell line is de‐
rived from parental MDA‐MB‐231 cells. MDA‐MB‐231 cells were 
subjected to increasing concentrations of paclitaxel (T1912, Sigma) 
until the cells acquire resistance to 0.2 mol/L of paclitaxel. The pacli‐
taxel resistance cell was then maintained in 0.2 mol/L of paclitaxel. 
For double thymidine block, cells were arrested with 2 mmol/L thy‐
midine (Sigma) medium for 19 hours. After cells were washed three 
times with phosphate‐buffered saline (PBS) and released into fresh 
medium for 9 hours, they were then treated with thymidine for an 
additional 16 hours. To synchronize cells in G2/M phase, cells were 
treated with 40 ng/mL nocodazole (Sigma) for 16 hours.
2.2 | In vivo ubiquitination assays and colony 
formation assay
Cells were transfected with HA‐ubiquitin and pcDNA3‐FOXM1, 
with either Aur‐A or empty vector. After that, cells were treated 
with MG132 for the last 6 hours of transfection and lysed with ubiq‐
uitin assay buffer (6 mol/L guanidine‐HCl, 0.1 mol/L Na2HPO4/
Na2HPO4, 0.01 mol/L Tris‐HCl, 5 μmol/L imidazole, 10 μmol/L β‐
mercaptoethanol). Ubiquitinated proteins were eluted with elution 
buffer (200 μmol/L imidazole, 0.15 mol/L Tris‐HCl, pH 6.7, 30% 
glycerol, 0.72 M‐mercaptoethanol, 5% sodium dodecyl sulphate). 
The presence of ubiquitinated FOXM1 was analysed by immuno‐
blotting with FOXM1 antibody.20 For colony‐forming assay, 3 to 
5 × 103 cells were plated in triplicate in 6 cm plate. Twenty‐four 
hours later, treatment was initiated. After 14 to 17 days, cells were 
fixed and stained with crystal violet. Quantification was done 
using Adobe Photoshop. All P values were calculated using the 
Student's t test.
2.3 | Gene knock‐down using shRNA and siRNA
Gene silencing was performed using specific shRNAs delivered by 
a lentiviral system acquired from Sigma‐Aldrich (Shanghai, China), 
following the instructions provided. Briefly, to yield lentiviruses 
containing specific shRNA sequences, 293T cells were cotrans‐
fected with 2.5 μg pMD2.G and 7.5 μg psPAX2 packaging plasmids 
and 10 μg of the pLKO.1 plasmid containing the specific shRNA for 
24 hours. The lentivirus containing cultured medium was collected 
and stored at −80℃ as aliquots until further use. To deliver the 
specific shRNA construct, approximately 10% confluent cells were 
incubated with the lentivirus bearing specific shRNA in growth 
medium containing 8 mg/mL polybrene at 37℃ for 24 hours. The 
transduced cells were then selected with 2 mg/mL puromycin. For 
small interfering RNA assay, cells were cultured for 16 hours in 6‐
well plates before transfection. The siRNA oligonucleotides were 
as follows:
si‐Aur‐A‐1:5′‐AUGCCCUGUCUUACUGUCA‐3′;
si‐Aur‐A‐2:5′‐GGCAACCAGTGTACCTCAT‐3′;
si‐Aur‐A‐3:5′‐ATTCTTCCCAGCGCGTTCC‐3′;
si‐FOXM1‐1:5′‐GCACTATCAACAATAGCCTAT‐3′;
si‐FOXM1‐2:5′‐GCCAATCGTTCTCTGACAGAA‐3′;
si‐FOXM1‐3:5′‐GGACCACUUUCCCUACUUU‐3′;
control: 5′‐UUCUCCGAACGUGUCACGU‐3′.
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siRNA was transfected into cells using Lipofectamine 2000 
(Invitrogen) according to the manufacturer's instructions. To confirm 
down‐regulation efficacy, targeted genes were detected by Western 
blot.
2.4 | IP and Western blot analysis
Cells were harvested and lysed in immunoprecipitation (IP) buffer 
on ice for 20 minutes. The IP buffer consisted of 50 mmol/L Tris (pH 
7.5), 100 mmol/L NaCl, 5 mmol/L EDTA, 5 mmol/L EGTA, 1% NP‐40, 
5% glycerol, freshly added protease inhibitor cocktail, 2 mmol/L phe‐
nylmethylsulfonyl fluoride, and 2 mmol/L NaF and 2 mmol/L NaVO4 
as phosphatase inhibitors. Cell extracts were clarified by centrifuga‐
tion at 12 000 g for 5 minutes at 4°C. Protein concentrations were 
determined by the Bradford method with the Bio‐Rad protein assay 
reagent. For Western blot, cells were lysed in RIPA buffer and the 
protein concentrations determined by the Bradford assay. Equal 
amounts of cell extracts were subjects to electrophoresis on sodium 
dodecyl sulphate‐polyacrylamide gel and blotted onto nitrocellu‐
lose membrane (Millipore). After protein transfer, the membranes 
were blocked and then incubated with glyceraldehyde 3‐phosphate 
dehydrogenase (Ambion, ThermoFisher Scientific). The antibodies 
used were as follows: p‐AURKA (Thr288; Cell Signaling Technology, 
Gene Company Ltd), AURKA (Upstate, Gene Company Ltd), HA‐tag 
(Sigma), FOXM1 (Santa Cruz, C‐20) and GAPDH (Epitomics, Abcam). 
Membrane was incubated in primary antibodies at 4°C overnight. 
The membranes were then incubated for 1 hour at room temperature 
with the appropriate secondary antibodies. Proteins were detected 
with an enhanced chemiluminescence kit (Pierce, ThermoFisher 
Scientific).
2.5 | Real‐time RT–PCR
Total RNA was extracted using TRIzol reagent (Invitrogen), and used 
for generating cDNA using SuperScript III RT (Invitrogen) in the pres‐
ence of oligo‐dT primers. Real‐time reverse transcriptase‐PCR was 
performed using Platinum SYBR Green qPCR Super‐Mix (Invitrogen), 
with GAPDH (glyceraldehyde 3‐phosphate dehydrogenase) as the 
internal control.
2.6 | Immunohistochemical staining
Following informed consent and in accordance with the guidelines 
of the Institutional Review Boards, breast cancer specimens were 
collected from patients undergoing surgery at the Guangzhou first 
people's hospital, China. Paraffin‐embedded tissue blocks were sec‐
tioned for immunohistochemistry as described previously. The de‐
paraffinized sections were incubated in H2O2 (3%) for 10 minutes, 
blocked in 1% bovine serum albumin for 60 minutes and incubated 
with an anti‐AURKA antibody (1:200 dilution) or an anti‐FOXM1 an‐
tibody (1:100 dilution) at 4°C overnight. ImageJ software was used 
to measure FOXM1 and Aurora‐A scoring. The degree of score (0 to 
3+) is based on both image intensity and completeness of staining in 
tumour cells. The 1+ score was considered as low expression, and 
the score ≥ 2+ was considered as high expression.
2.7 | Statistical analysis
Statistical analyses were performed using the SPSS software, version 
16.0 (SPSS Inc) and with GraphPad Prism 5.0 (GraphPad Software 
Inc). The unpaired Student's t test was used to perform statistical 
analysis between two groups. Continuous and categorical variables 
were compared between groups, using the Mann‐Whitney test and 
one‐way ANOVA for non‐parametric continuous data. Pearson's 
correlation coefficient (r) was used to describe the correlation be‐
tween two variables. A value of P < .05 was considered statistically 
significant. The UALCAN web resource was used for analysing can‐
cer transcriptome data in TCGA database.21
3  | RESULTS
3.1 | Aurora‐A and FOXM1 are overexpressed and 
correlated in triple‐negative breast cancer
To investigate the significance of Aurora‐A and FOXM1 in breast 
cancer, we evaluate cancer transcriptome in TCGA database at 
UALCAN web resource.21 As shown in Figure 1A, Aurora‐A is over‐
expressed in clinical breast cancer sample, with significantly higher 
in triple‐negative breast cancer (Figure 1B). Consistently, FOXM1 
is also overexpressed in clinical breast cancer sample and signifi‐
cantly higher in triple‐negative breast cancer (Figure 1C,D). There 
is a significant positive correlation between Aurora‐A and FOXM1 
in breast cancer (r = .53, P < .01; Figure 1E). Next, we analysed the 
expression level of Aurora‐A and FOXM1 in a panel of 66 TNBC sam‐
ples and 11 benign breast tumour samples from GuangZhou First 
People’ hospital. Aurora‐A was highly expressed in 54 samples and 
lowly expressed in 12 samples while FOXM1 was highly expressed 
in 43 samples and lowly expressed in 23 samples. Aurora‐A and 
FOXM1 were co‐expressed in 39 TNBC samples, which was consist‐
ent with the TCGA database (P < .05; Figure 1F). The representa‐
tive picture of high expression and low expression was shown in 
Figure 1G. Together, our data suggest that Aurora‐A and FOXM1 are 
co‐expressed in clinical TNBC samples, supporting the critical role of 
Aurora‐A and FOXM1 in TNBC growth.
3.2 | Aurora‐A stabilizes FOXM1 during cell cycle
Next, we test whether Aurora‐A regulates FOXM1 in TNBC cells, 
MDA‐MB‐231 cells were transfected with Aurora‐A siRNA or a 
control siRNA. Immunoblots showed that depletion of Aurora‐A 
obviously led to a decrease of FOXM1 protein levels, which could 
account for the reduced expression of FOXM1 target gene cyclinB1 
(Figure 2A, lane 2 and lane 3). We speculated that Aurora‐A regu‐
lates the protein stability of FOXM1. Control and si‐Aurora‐A cells 
were treated with cycloheximide to block new protein synthesis and 
were harvested at different time‐points afterwards. Under these 
     |  6445YANG et Al.
6446  |     YANG et Al.
conditions, depletion of Aurora‐A obviously reduced the half‐life 
of endogenous FOXM1 (Figure 2B, lane 4, 5, 6 vs lane 10, 11, 12). 
Conversely, transient transfection of Aur‐A expression vectors in 
231 cells enhanced steady‐state levels of FOXM1, which indicated 
an increase in FOXM1 stability (Figure 2C, lane 3, 4, 5 vs lane 8, 9, 
10). To further test Aurora‐A‐mediated FOXM1 stability, MG132 was 
incubated in medium to prevent degradation by the 26S proteasome. 
The protein level of FOXM1 was partly rescued by adding MG132 
(Figure 2D, lane 2, 3 vs lane 5, 6). Because Aurora‐A and FOXM1 
were critical cell cycle protein of G2/M phase, we test whether 
F I G U R E  1   Aurora‐A and FOXM1 are overexpressed and correlated in triple‐negative breast cancer. A, Transcript of Aurora‐A was 
evaluated in breast cancer in TCGA database. Triple‐negative breast cancer is defined by low or no expression of progesterone receptor (PR), 
oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). B, Transcript of Aurora‐A was evaluated in different breast 
cancer subtypes in TCGA database. C, Transcript of FOXM1 was evaluated in breast cancer in TCGA database. D, Transcript of FOXM1 was 
evaluated in different breast cancer subtypes in TCGA database. E, The correlation between Aurora‐A and FOXM1 in TNBC was evaluated in 
TCGA database by Pearson's correlation test. F, FOXM1 and Aurora‐A levels were evaluated in 66 TNBC specimens. Statistical comparisons 
were made using chi‐square test. G, Expression of Aurora‐A and FOXM1 was examined via IHC staining in TNBC specimens. Representative 
picture was shown
F I G U R E  2   Aurora‐A stabilizes FOXM1 protein during cell cycle in late M phase and early G1 phase. A, Western blot analysis with 
indicated antibodies in control (si‐C) and Aurora‐A knock‐down (si‐A) MDA‐MB‐231 cells. B, Western blots analysis of the FOXM1 stability in 
MDA‐MB‐231 cells expressing either control siRNA or siRNA targeting Aurora‐A. Cells were treated with cycloheximide (CHX). Lysates were 
prepared at the indicated times after addition of CHX and probed with the indicated antibodies. C, Stabilization of FOXM1 by expression 
of Aurora‐A. Cells were transfected with control vectors and Aurora‐A overexpression vectors as indicated. D, Cells were transfected with 
si‐control and si‐Aurora‐A small RNA. Subsequently, MG‐132 was added to cells at last 6 h and lysates were analysed by Western blot. E, 
Cells were arrested at the G1‐S boundary by double thymidine block, released into fresh medium, and harvested at the indicated times. Cell 
lysates were subjected to Western blot assays with indicated antibodies. F, Cells were released from nocodazole block (prometaphase) for 
the indicated times. Cell extracts were subjected to Western blotting with indicated antibody. G, Cells were transfected with si‐control and 
si‐Aurora‐A small RNA, and real‐time RT‐PCR was performed to evaluate the M phase cell cycle genes
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Aurora‐A regulates FOXM1 during cell cycle. After cells were syn‐
chronized in G1/S phase by a double thymidine block, protein ex‐
tracts were prepared at indicated time‐point following thymidine 
removal and analysed by immunoblotting. As shown in Figure 2E 
(lane 2 to 6), the level of FOXM1 increased during the late S phase 
(after 3 hours of thymidine removal) and the transition between G2 
phase and mitosis (at the time‐point of 9‐12 hours). Aurora‐A and 
FOXM1 were simultaneously accumulated gradually from S phase 
to G2 phase and peaked in mitosis. Interestingly, both Aurora‐A and 
FOXM1 were not degraded at the late M phase and early G1 phase 
(at the time‐point of 14 hours). This result suggested that Aurora‐A 
and FOXM1 undergone almost identical changes during cell cycle 
and they were stable at late M phase and early G1 phase in TNBC 
cells, which was different from other cells.20 To further investigate 
the role of Aurora‐A in the stabilization of the FOXM1 protein dur‐
ing cell cycle, we performed siRNA transfection experiments with 
synchronized MDA‐MB‐231 cells. Cells were synchronized in M 
phase by treating them with nocodazole for 16 hours (Figure 2F). 
After nocodazole was removed, the cells were allowed progression 
through the G1 and S phases. The synchronized cells at indicated 
time‐point were harvested. Depletion of Aurora‐A in MDA‐MB‐231 
cells obviously reduced the levels of FOXM1 protein after 3 hours of 
nocodazole removal (a time‐point corresponding to late M phase), 
suggesting a role of Aurora‐A in the stabilization of FOXM1 in the 
late M and early G1 phases of the cell cycle. Furthermore, down‐reg‐
ulation of Aurora‐A by siRNA significantly reduced the downstream 
genes of FOXM1 in M phase (Figure 2G). Taken together, the regu‐
lation of Aurora‐A on FOXM1 in the cell cycle of TNBC cells is not 
restricted to the G2/M phase when the kinase activity of Aurora‐A 
is highest, but also in the M/G1 transition.
3.3 | Aurora‐A up‐regulates FOXM1 in 
triple‐negative breast cancer via kinase‐
independent manner
Previously, we reported that Aurora‐A regulated FOXM1 at tran‐
scription level via kinase‐independent manner was essential for 
breast cancer stem cell.17 To test whether the kinase activity of 
Aurora‐A is essential for the degradation of the FOXM1 protein 
in TNBC, we inhibited the kinase activity of Aurora‐A by treat‐
ing MDA‐MB‐231 and MCF‐7 cells with Aurora‐A inhibitor VX680. 
Treatment of VX680 caused obviously decreased FOXM1 level in 
MCF‐7 cells, whereas in MDA‐MB‐231 cells there is no obvious 
reduction in FOXM1 levels at indicated concentration (Figure 3A 
lane 2‐6 vs 3B lane 2‐6). Since MCF‐7 is ER‐positive cells, we 
suggest that kinase activity is important for Aurora‐A regulating 
F I G U R E  3   Aurora‐A up‐regulates FOXM1 in triple‐negative breast cancer in kinase‐independent manner. A, MCF‐7 cells were treated 
with indicated dose of VX680 and subjected to Western blot analysis to determine the protein expression levels. B, MDA‐MB‐231 cells were 
treated with indicated dose of VX680, and Western blot analysis was done to determine the protein expression levels. C, MDA‐MB‐231 cells 
were treated with VX680 (0.6 μmol/L) for 8 h, and after that, cells were co‐treated with cycloheximide (CHX) at the indicated time. Lysates 
were prepared and probed with the indicated antibodies. D, MDA‐MB‐231 cells were transfected with the indicated control vectors and 
Aur‐A expression vectors. Western blot analysis was done to determine the protein expression levels
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FOXM1 in ER‐positive cells, whereas in TNBC cells it is kinase in‐
dependent. To further investigate the requirement of Aurora‐A 
kinase activity in the degradation of the FOXM1 protein, cells 
were simultaneously treated with cycloheximide and VX680 or 
cycloheximide alone to block new protein synthesis and kinase 
activity. The result showed there was no significant difference in 
FOXM1 level between the VX680 treated cells and control cells 
(Figure 3C, lane 2, 3 vs lane 5, 6). Consistently, overexpression 
of Aurora‐A up‐regulated FOXM1 and its downstream factor cy‐
clinB1 in MDA‐MB‐231 cells (Figure 3D, lane 2).
3.4 | Aurora‐A directly binds and attenuates 
ubiquitin of FOXM1
To explore the mechanisms by which knock‐down of Aurora‐A 
reduced FOXM1 protein, we conducted IP assays to test whether 
Aurora‐A interacted with FOXM1 protein. IP assays showed 
that there is a specific interaction between Aurora‐A and the 
FOXM1 protein (Figure 4A, lane 3), supporting the notion that 
FOXM1 is a target of Aurora‐A. Next, we performed in vivo ubiq‐
uitination assays to see whether Aurora‐A regulates the ubiq‐
uitin of FOXM1. 293T cells were transfected with HA‐ubiquitin 
and FOXM1 expression vectors along with either empty vector 
or Aurora‐A expression vector. Twenty‐four hours following 
transfection, cells were treated with MG132 for 6 hours. The lev‐
els of ubiquitinated FOXM1 protein were analysed by Western 
blot analysis using FOXM1 antibody. As shown in Figure 4B (lane 
1 vs lane 2), expression of Aurora‐A decreased the ubiquitination 
of FOXM1. To analyse the endogenous proteins, cells were de‐
pleted of Aurora‐A by siRNA transfection. The cells were treated 
with MG132 for 6 hours before being harvested and subjected 
to IP assays using either antibody against FOXM1 or control 
mouse immunoglobulin G, and immunoprecipitates were ana‐
lysed by Western blotting with ubiquitin antibody. Clearly, both 
depletion of Aurora‐A and inhibition of its kinase activity caused 
increased ubiquitination of FOXM1 (Figure 4C, lane 3 and lane 
4). Interestingly, inhibition of Aurora‐A kinase activity also in‐
creased the ubiquitination of FOXM1, indicating that the kinase 
activity of Aurora‐A may decrease the ubiquitination of FOXM1 
in triple‐negative breast cancer.
3.5 | Aurora‐A and FOXM1 are essential for the 
growth of triple‐negative breast cancer
To investigate whether the growth of TNBC cells was dependent 
on Aurora‐A and FOXM1, we designed retroviral shRNA vectors 
targeting Aurora‐A and FOXM1 and tested them in MDA‐MB‐231 
cells. After transfection of sh‐Aurora‐A and sh‐FOXM1 vector, 
F I G U R E  4   Aurora‐A directly binds and attenuates ubiquitin of FOXM1. A, IP assay was performed to detect the interaction of 
endogenous Aurora‐A and FOXM1 in MDA‐MB‐231. B, Cells were transfected with HA‐ubiquitin (HA‐ubi) and FOXM1 expression vector 
along with Aurora‐A expression vector or empty vector. MG‐132 (25 mmol/L) was added to block proteasomal degradation. Lysates of 
the cells were subjected to IP using HA antibody. The ubiquitinated proteins were analysed for polyubiquitination of the FOXM1 protein 
by Western blot assays. C, Cells were transfected with siRNA against Aurora‐A or with control siRNA or treated with VX680. Four hours 
before harvesting, MG‐132 (25 mmol/L) was added to block proteasomal degradation. Lysates of the cells were subjected to IP using FOXM1 
antibody. Western blot was performed to analyse the ubiquitin status of FOXM1
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the number of colonies was significantly reduced compared with 
control cells (Figure 5A). Conversely, elevation of Aurora‐A and 
FOXM1 levels using recombinant retroviruses significantly in‐
creased the number of colony formation (Figure 5B). Next, we 
investigate whether FOXM1 is essential for Aurora‐A‐mediated 
inhibition of growth in TNBC cells. MDA‐MB‐231 cells were si‐
multaneously transfected with sh‐Aurora‐A and FOXM1 over‐
expression vector. The result showed that colony formation was 
rescued by FOXM1 overexpression, indicating that the reduction 
in FOXM1 levels is the critical mechanism by which depletion of 
Aurora‐A inhibits proliferation (Figure 5C). To provide additional 
evidence that Aurora‐A and FOXM1 is necessary for growth and 
survival of TNBC cells, MAD‐MB‐231 cells transfected with sh‐
Aurora‐A and sh‐FOXM1 were seeded on 12‐well plate, and after 
that, cells were harvested for cell counting at indicated time‐point. 
The growth curves showed that both expression of sh‐Aurora‐A 
and sh‐FOXM1 significantly inhibited proliferation of MDA‐
MB‐231 cells (Figure 5E). Furthermore, we found that depletion 
of Aurora‐A in MDA‐MB‐231 cells reduced the mRNA levels of 
FOXM1 (Figure 5D), arguing that Aurora‐A regulates FOXM1 lev‐
els via both transcription and posttranscriptional mechanisms in 
TNBC cells. We concluded that Aurora‐A up‐regulating FOXM1 
was essential for the growth of TNBC cells.
3.6 | Aurora‐A enhances paclitaxel resistance in 
triple‐negative breast cancer
Previous study reported that FOXM1 mediates resistance to pa‐
clitaxel.22 We sought to investigate whether increased Aurora‐A 
induces resistance to paclitaxel. To prove the hypothesis, we sta‐
bly introduced Aurora‐A expression cDNA in MDA‐MB‐231 cells. 
Cells were treated with 10 μg/mL of paclitaxel for 0, 24, 48, 72 or 
96 hours. Western blot of Aurora‐A and FOXM1 levels showed that 
in control cells the levels of both Aurora‐A and FOXM1 decreased 
with treatment at 72 hours, whereas there is no significant decrease 
of both Aurora‐A and FOXM1 in Aurora‐A overexpression cells 
(Figure 6A, lane 4, 5 vs lane 9, 10). Growth curves showed that the 
overexpression of Aurora‐A led to significant increase in cell viabil‐
ity upon paclitaxel treatment (Figure 6B). To further investigate the 
role of Aurora‐A in paclitaxel resistance, we generated paclitaxel‐re‐
sistant cell line. Aurora‐A levels in parental and resistant lines were 
analysed by Western blot. Interestingly, both Aurora‐A and FOXM1 
F I G U R E  5   Aurora‐A and FOXM1 are essential for the growth of triple‐negative breast cancer. A, The effect of depletion of Aurora‐A and 
FOXM1 on MDA‐MB‐231 cells was tested by colony assays using shRNA. B, The effect of overexpression of Aurora‐A and FOXM1 on MDA‐
MB‐231 cells was tested by colony assays using expression vectors. C, The sh‐Aurora‐A cell line was transfected with empty or FOXM1 
overexpression vectors. Colony formation assay was used to test the cell proliferation. Three plates were counted and averaged. Error bars 
show standard deviation of triplicate samples. D, After RNA interfering by control siRNA and Aurora‐A‐specific siRNA, the mRNA levels of 
Aurora‐A and FOXM1 were analysed by real‐time quantitative PCR normalized with GAPDH mRNA levels. E, Growth curve of MDA‐MB‐231 
cells infected with control shRNAs or shRNAs targeting Aur‐A or FOXM1. Cells were counted at indicated time to evaluate the cell viability. 
Columns, mean of three independent experiments in triplicate; bars, ±SD. **P < .01, ***P < .001. Representative wells were shown
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levels were elevated in paclitaxel‐resistant cell lines. After treatment 
with paclitaxel, Aurora‐A and FOXM1 levels simultaneously reduced 
in parental cells at 48 and 72 hours, whereas in paclitaxel‐resist‐
ant cells there is no significant change (Figure 6C, lane 2, 3, 4 vs 
lane 6, 7, 8). Growth curves also revealed significant differences be‐
tween parental and resistant cells (Figure 6D). These data indicate 
that Aurora‐A can protect breast cancer cells from treatment with 
paclitaxel.
Studies from ours and others reported that the antibiotic drug 
thiostrepton targeted FOXM1 and greatly inhibited growth of 
TNBC cells.23,24 We sought to explore whether thiostrepton could 
reverse paclitaxel resistance. Notably, both Aurora‐A and FOXM1 
were reduced when treated with thiostrepton alone or in com‐
bination with paclitaxel (Figure 6E, lane 4 and lane 5). However, 
combination treatment with paclitaxel and Aurora‐A kinase in‐
hibitor VX‐680 has slight effect on Aurora‐A and FOXM1 levels. 
Proliferative assays showed that paclitaxel‐resistant cells exhibited 
a significant decrease in cell viability when treated with thiost‐
repton alone or in combination with paclitaxel (Figure 6F). These 
results indicated that Aurora‐A confers resistance by up‐regulat‐
ing FOXM1. It is worth to mention that Aurora‐A kinase inhibi‐
tor VX680 in combination with paclitaxel can significantly inhibit 
growth of resistant cells, which indicated other mechanisms may 
account for VX680 effect.
4  | DISCUSSION
We reported here that Aurora‐A promotes proliferation of TNBC 
cells by stabilizing FOXM1. Knock‐down of Aurora‐A significantly 
suppressed cell proliferation and colony formation in TNBC cell 
lines. Notably, Aurora‐A‐mediated reduced colony formation was 
rescued by FOXM1 overexpression, indicating that the reduction 
in FOXM1 levels is the critical mechanism by which depletion of 
Aurora‐A inhibits proliferation, and this function is critical for the 
growth of TNBC cells. We also observed that aberrant expression of 
FOXM1 and Aurora‐A is highly correlated in clinical TNBC samples, 
providing clinical evidence for Aurora‐A regulating FOXM1 in TNBC. 
Depletion of Aurora‐A in MDA‐MB‐231 cells not only reduced the 
steady‐state levels of FOXM1 protein but also led to decrease in 
FOXM1 mRNA levels (Figure 4D), arguing that Aurora‐A regulates 
FOXM1 level via both transcriptional and posttranscriptional mech‐
anisms. Interestingly, in TNBC cells the kinase activity of Aurora‐A 
is not involved in this function of Aurora‐A, whereas in ER‐positive 
F I G U R E  6   Aurora‐A enhances paclitaxel resistance in triple‐negative breast cancer. A, Control cells and Aurora‐A overexpression cells 
were treated with 0.2 μmol/L of paclitaxel, and Western blot analysis was done to determine the protein expression levels of Aurora‐A, 
FOXM1 and GAPDH. B, Growth curves of control cells and Aurora‐A overexpression cells that were treated with 0.2 μmol/L of paclitaxel. 
Cells were harvested and counted at indicated time. C, Parental and paclitaxel‐resistant MDA‐MB‐231 cells were treated with 0.2 μmol/L of 
paclitaxel for 0, 12, 24, 48 and 72 h. Protein lysates were analysed by Western blotting using specific antibodies. D, Parental and paclitaxel‐
resistant MDA‐MB‐231 cells were treated with 0.2 μmol/L of paclitaxel. Cells were counted at indicated time to evaluate cell viability. E, 
Paclitaxel‐resistant MDA‐MB‐231 cells were treated with different drug alone or in combination. Western blot was performed to analyse 
the Aurora‐A and FOXM1 level. GAPDH used as loading control. F, Paclitaxel‐resistant MDA‐MB‐231 cells were treated with different drug 
alone or combination. MTT assay was performed to evaluate cell viability. Bars, ±SD. ***P < .001
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cells, such as MCF‐7, the kinase activity of Aurora‐A is probably 
important, as FOXM1 is obviously down‐regulating by Aurora‐A ki‐
nase inhibitor VX680. Thus, inhibition of Aurora‐A kinase activity 
using small molecules may not enough to block a critical oncogenic 
function of Aurora‐A in triple‐negative breast cancer. Indeed, sev‐
eral studies were currently being evaluated in preclinical models of 
TNBC.25‐28 Some models are sensitivity to ENMD‐2076, a kinase in‐
hibitor of Aurora‐A, by induction of apoptosis, whereas some models 
exhibiting intrinsic or acquired resistance to treatment.26 The result 
from our study suggested that inhibition of both kinase‐dependent 
and kinase‐independent function is required for TNBC patients.
Several mechanisms are considered responsible for the ele‐
vated FOXM1 in cancer, including amplification of the FOXM1 
locus, increased stability of FOXM1 and enhanced transcription 
of FOXM1.29 FOXM1 stability or expression in cancer cells can be 
increased via the interaction with different types of proteins. For 
example, the Wnt signalling pathway inhibits FOXM1 degradation,30 
and the direct interaction with nucleophosmin and phosphorylation 
by Chk2 complexes stabilizes FOXM1 protein.31,32 E2F, c‐Myc and 
hypoxia‐inducible factor‐1 directly bind to the FOXM1 promoter and 
stimulate its expression.33‐35 Previously, we reported that kinase‐
dead Aurora‐A could effectively transactivate the FOXM1 promoter 
through a Forkhead response element and promote the self‐renewal 
of breast cancer stem cell.17 In the present study, we demonstrated 
that in TNBC cells, Aur‐A binds to and stabilizes FOXM1 by attenu‐
ating its ubiquitin. FOXM1 is a key regulator of cell cycle.36 Up‐reg‐
ulation of FOXM1 in cancer cells leads to uncontrolled cell division 
and genomic instability.29,37,38 In normal cell cycle, FOXM1 is syn‐
thesized and degraded in every cycle of cell division. It is reported 
that FOXM1 is polyubiquitinated by APC/CCdh1 for degradation 
by the proteasome in late mitosis and early G1‐phase.20 The degra‐
dation of FOXM1 in the late mitosis and early G1‐phase is import‐
ant for regulated entry into S phase. Previous study reported that 
FOXM1 exhibited obvious reduction after 3 hours of nocodazole 
removal (late mitosis and early G1 phase).20,39 We observed that the 
FOXM1 did not exhibit a reduction after 3 hours of nocodazole re‐
moval in TNBC cells. However, in Aurora‐A siRNA‐transfected cells, 
the FOXM1 protein level decreased significantly in late mitosis and 
early G1 phase of the cell cycle (Figure 1F), suggesting Aurora‐A pre‐
vented the loss of FOXM1 in the late mitosis and early G1 phase 
in TNBC cells. Therefore, the effect of Aurora‐A regulating FOXM1 
in TNBC cells is not restricted to the G2/M phase when the kinase 
activity of Aurora‐A is highest. We concluded that up‐regulation of 
Aurora‐A led to increased FOXM1 level in cell cycle, with the effect 
being strongest in the late mitosis and early G1 phase, providing an 
explanation that Aurora‐A enhanced proliferation of TNBC cells by 
promoting G1/S transition during cell cycle.
High expression of Aurora‐A was reported a predictive maker 
for poor prognosis and drug resistance in triple‐negative breast 
cancer, which is associated with a greater risk of recurrence and 
relapse.13,14,40 To date, chemotherapy remains the only possible 
therapeutic option in the treatment of TNBC.2,4,41‐45 Paclitaxel is 
a commonly used chemotherapeutic agent for TNBC. However, 
some of the patients undergone recurrence after short‐term re‐
spond and many others fail to respond to this drug, indicating that 
TNBC cells can possess either acquired or inherent resistance to 
this drug which poses a significant clinical challenge. Previous study 
from our and other laboratory reported that Aurora‐A plays an im‐
portant role in drug resistance.46‐48 Aurora‐A stabilizes survivin 
in gastric cancer to promote drug resistance.49 High expression 
level of Aurora‐A was involved in tamoxifen resistance.46 In the 
present study, we demonstrated that high levels of Aurora‐A offer 
TNBC cells an additional growth advantage and protection against 
paclitaxel. Consistently, the paclitaxel‐resistant TNBC cells exhibit 
high expression of Aurora‐A and cannot be down‐regulated by pa‐
clitaxel compared to parental cells. The mechanisms by which cells 
acquire resistance are multiple and complex. It has been shown 
that FOXM1 mediated resistance to chemotherapeutic drugs in 
breast cancer cells.22,50 Jimmy et al reported that cisplatin‐resis‐
tant breast cancer cells could be reversed by the FOXM1 inhibitor 
thiostrepton.22 We observed that FOXM1 was also up‐regulated 
in paclitaxel‐resistant cells. Combination of FOXM1 inhibitor thio‐
strepton and paclitaxel treatment can reverse acquired paclitaxel 
resistance in TNBC cells and significantly inhibiting cell prolifera‐
tion. These results show the likely mechanism by which Aur‐A con‐
fers resistance is by preventing the degradation of FOXM1, and 
this function is kinase independent. A study using in vivo model 
of triple‐negative breast cancer reported that Aurora‐A kinase 
inhibitor MLN8237 and taxanes have synergistic antitumour ac‐
tivity.51 We also found a synergistic activity between VX680 and 
paclitaxel in TNBC cells, indicating other mechanisms are involved 
in the antitumour activity of aurora kinase inhibitor. Interestingly, 
the Aurora‐A and FOXM1 could be simultaneously reduced by 
thiostrepton in paclitaxel‐resistant TNBC cells. Together, our re‐
sult suggested that thiostrepton inhibited growth of paclitaxel‐re‐
sistant cells by down‐regulating both Aurora‐A and FOXM1 and 
could be a therapeutic strategy for reversing paclitaxel chemore‐
sistance in TNBC patients.
Overall, the mechanism we revealed in this study provided in‐
sight into an additional pathway through which Aurora‐A regulates 
FOXM1 in triple‐negative breast cancer. Aurora‐A‐mediated sta‐
bilization of FOXM1 could reflect its kinase‐independent role in 
enhanced proliferation capacity of TNBC cancer cells. Although in‐
hibition of Aurora‐A kinase was a promising regimen for TNBC can‐
cer therapy, the results presented here suggested that the use of an 
antibiotic drug thiostrepton, which is capable of directly down‐regu‐
lating Aurora‐A and FOXM1 level, could synergize with paclitaxel to 
reverse paclitaxel chemoresistance in TNBC. Our findings provide 
evidence for using thiostrepton as a new therapeutic strategy for 
paclitaxel‐resistant TNBC patients.
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